Drugs / A. Chilensis
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04955327 | Mar 2021 → Feb 2022 | respiratory tract infectious disorder | Vedic Lifesciences Pvt. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A. Chilensis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04955327 ↗ |
| Known as | Aristotelia Chilensis | “Maqui contains Maqui Berry Extract of Aristotelia Chilensis (10% Anthocyanidin, 8% Delphinidin) belonging to the family of Elaeocarpaceae, which has been known for its use in...” NCT04955327 ↗ |